phrykt

Nuvation Bio Inc. (NUVB): who owns it and who trades it

As of Nov 16, 2026, NUVB insiders reported 16 open-market sales worth $9.2M and 1 purchase worth $118K in the last 12 months, with 38% of the sale value made under pre-set 10b5-1 plans. The largest seller was Gary Hattersley (CHIEF SCIENTIFIC OFFICER), with $3.4M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Nuvation Bio

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NUVB

243 funds and institutions reported NUVB shares worth $1.3B at the end of Q2 2026, about 68% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.

Funds and institutions (13F) 68%Everyone else 32%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.0%
BlackRock, Inc.7.9%
Decheng Capital LLC7.5%
Vanguard Capital Management LLC3.4%
Omega Fund Management, LLC2.3%
Laurion Capital Management LP2.2%
State Street Corp2.1%
Geode Capital Management, LLC1.8%
Duquesne Family Office LLC1.3%
American Century Companies Inc1.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)52.23M15.00%$297M+0%
BlackRock, Inc.27.63M7.94%$157M+10%
Decheng Capital LLC25.95M7.45%$147MNo change
Vanguard Capital Management LLC11.92M3.42%$67.7M+3%
Omega Fund Management, LLC8.08M2.32%$45.9MNo change
Laurion Capital Management LP7.82M2.25%$44.4MNo change
State Street Corp7.37M2.12%$41.9M+9%
Geode Capital Management, LLC6.24M1.79%$35.5M+7%
Duquesne Family Office LLC4.54M1.30%$25.8MNo change
American Century Companies Inc4.50M1.29%$25.6M+55%
Bank of America Corp3.53M1.01%$20M+10%
Tang Capital Management LLC3.30M0.95%$18.7M+5%
Redmile Group, LLC3.03M0.87%$17.2M-4%
Vanguard Portfolio Management LLC2.69M0.77%$15.3M+18%
AQR Capital Management LLC2.36M0.68%$13.4M+18%
Northern Trust Corp2.32M0.67%$13.2M+16%
Algert Global LLC2.28M0.65%$12.9M+24%
Hrt Financial LP2.21M0.63%$12.5M–
Charles Schwab Investment Management Inc2.06M0.59%$11.7M+3%
Sixth Street Partners Management Company, L.P.2.06M0.59%$11.7M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, NUVB insiders reported $118K of open-market purchases and $9.2M of sales. 38% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$118K
1 trades, 1 people
Sales, 12 months
$9.2M
16 trades, 6 people
Sales under a 10b5-1 plan
38%
Share of sale value
Latest trade
Aug 19, 2026
Filed Aug 21, 2026

Purchases and sales by month

$1.4M$1.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 19, 2026Gary HattersleyCHIEF SCIENTIFIC OFFICERSale plan100,000$7.09$709KForm 4
Jun 23, 2026Stacy MarkelCHIEF PEOPLE OFFICERSale plan125,000$6.03$754KForm 4
Jun 23, 2026Kerry WentworthCHIEF REGULATORY OFFICERSale plan63,000$6.02$379KForm 4
Jun 23, 2026Philippe SauvageCFOSale plan47,668$6.01$286KForm 4
Jun 9, 2026Robert MashalDirectorPurchase25,000$4.73$118KForm 4
Apr 17, 2026Kerry WentworthCHIEF REGULATORY OFFICERSale plan36,750$5.01$184KForm 4
Apr 17, 2026Dongfang LiuCHIEF MEDICAL OFFICERSale plan50,000$5.02$251KForm 4
Apr 6, 2026Kerry WentworthCHIEF REGULATORY OFFICERSale plan200,000$4.52$904KForm 4
Dec 1, 2025Dongfang LiuCHIEF MEDICAL OFFICERSale150,000$7.82$1.2MForm 4
Nov 26, 2025Dongfang LiuCHIEF MEDICAL OFFICERSale10,000$8.00$80KForm 4
Nov 25, 2025Dongfang LiuCHIEF MEDICAL OFFICERSale10,000$7.50$75KForm 4
Nov 20, 2025Gary HattersleyCHIEF SCIENTIFIC OFFICERSale69,051$7.23$499KForm 4
Nov 20, 2025Gary HattersleyCHIEF SCIENTIFIC OFFICERSale300,000$7.23$2.2MForm 4
Nov 20, 2025Dongfang LiuCHIEF MEDICAL OFFICERSale20,000$7.00$140KForm 4
Nov 19, 2025David C. HanleyCHIEF TECHNICAL OPERATIOSale200,000$7.14$1.4MForm 4
Nov 19, 2025Dongfang LiuCHIEF MEDICAL OFFICERSale15,000$5.10$76.5KForm 4
Nov 17, 2025Dongfang LiuCHIEF MEDICAL OFFICERSale15,000$4.77$71.5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Gary HattersleyCHIEF SCIENTIFIC OFFICER–$3.4MAug 19, 2026
Dongfang LiuCHIEF MEDICAL OFFICER–$1.9MApr 17, 2026
Kerry WentworthCHIEF REGULATORY OFFICER–$1.5MJun 23, 2026
David C. HanleyCHIEF TECHNICAL OPERATIONS–$1.4MNov 19, 2025
Stacy MarkelCHIEF PEOPLE OFFICER–$754KJun 23, 2026
Philippe SauvageChief Financial Officer–$286KJun 23, 2026
Robert MashalDirector$118K–Jun 9, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NUVB short interest

High short interest. 17.6% of NUVB shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 20%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 62.00M NUVB shares were sold short, 17.6% of the shares outstanding, down 1.9% from the report before. At the average daily volume of 4.96M shares, buying them all back would take about 12.5 trading days (days to cover).

Shares short, % of all shares

17.6%May 15Oct 3018.6%

Days to cover

12.5May 15Oct 3015.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202662.00M17.56%-2%4.96M12.5
Oct 15, 202663.22M18.01%+7%6.55M9.7
Sep 30, 202658.86M16.76%+1%4.24M13.9
Sep 15, 202658.17M16.57%+7%5.34M10.9
Aug 31, 202654.26M15.45%+2%5.09M10.7
Aug 14, 202653.22M15.16%-0%6.00M8.9
Jul 31, 202653.42M15.34%-4%6.14M8.7
Jul 15, 202655.67M15.99%+2%6.93M8.0
Jun 30, 202654.36M15.61%+11%11.72M4.6
Jun 15, 202648.92M14.05%-9%5.08M9.6
May 29, 202653.67M15.41%+4%3.74M14.3
May 15, 202651.49M14.79%+2%5.17M10.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Nuvation Bio company events

Nuvation Bio filed 10 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jul 6, 2026AnnouncementThe Company issued a press release announcing the issuance of the additional Notes pursuant to the Greenshoe Exercise and the entry into the additional capped call confirmations. Filing
  4. Jun 30, 2026AgreementNuvation Bio Inc. completed its registered underwritten public offering of $250.0 million of 0.75% Convertible Senior Notes due 2032, pursuant to the Underwriting Agreement, dated June 25, 2026 with Jefferies LLC, Citigroup Global Markets Inc., and Cantor Fitzgerald & Co. as representatives of the… Filing
  5. May 27, 2026VoteReported shareholder vote results. Filing
  6. May 4, 2026ResultsReleased financial results. Filing
  7. Mar 2, 2026ResultsReleased financial results. Filing
  8. Jan 12, 2026AgreementNuvation Bio Inc. entered into a License and Collaboration Agreement with Eisai Co., Ltd. Filing
  9. Nov 26, 2025AnnouncementThe Company announced its decision to discontinue development of NUV-1511, the first compound in its first-of-its-kind drug-drug conjugate (DDC) program. Filing
  10. Nov 17, 2025AnnouncementPositive results from a Phase 2 study of safusidenib in Japanese patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas were published in the online journal of Neuro-Oncology. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Nuvation Bio financials

Famous investors that hold NUVB

6 of the 50 well-known investors we track reported holding NUVB in their latest 13F filing. The largest position is Ken Griffin's, worth $13.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20262.37M$13.3M0.0%+19%
Stanley Druckenmiller · Duquesne Family OfficeQ3 20262.27M$12.7M0.3%-50%
Jim Simons · Renaissance TechnologiesQ3 20261.32M$7.4M0.0%-2%
Israel Englander · Millennium ManagementQ3 2026700,196$3.9M0.0%+88%
Paul Tudor Jones · Tudor Investment CorpQ3 2026267,032$1.5M0.0%New
David Einhorn · Greenlight Capital (DME)Q3 202634,995$196K0.0%No change

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Nuvation Bio Inc. (NUVB) stock

Who owns the most NUVB stock?

The largest reported owner of Nuvation Bio Inc. (NUVB) is FMR LLC (Fidelity), with 15.0% of the company. In total, 243 funds and institutions reported holding NUVB at the end of Q2 2026, together about 68% of the shares. See the largest owners.

Are NUVB insiders buying or selling?

In the last 12 months, NUVB insiders reported 1 open-market purchase worth $118K and 16 sales worth $9.2M. The latest trade was on Aug 19, 2026. See every trade.

What is the short interest in NUVB?

As of Oct 30, 2026, 62.00M NUVB shares were sold short, 17.6% of the shares outstanding, down 1.9% from the report before. At the average daily volume of 4.96M shares, buying them all back would take about 12.5 trading days (days to cover). See the history.

Which famous investors hold NUVB?

6 of the 50 well-known investors we track reported NUVB in their latest 13F filing, including Ken Griffin, Stanley Druckenmiller, Jim Simons. The largest position is worth $13.3M. See all holders.

Executive pay

Nuvation Bio's chief executive was paid a total of $3.9M for the year ended Dec 31, 2025, up 4% from $3.7M the year before. In the last 12 months, Nuvation Bio's executives and directors bought $118K of stock on the open market and sold $9.2M.

Chief executive, total pay$3.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$27.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.